Oslo-based Nordic Nanovector has elected Joanna Horobin to its board as Non-executive Board Director. She replaces Renee Tannenbaum who stepped down from the board for personal reasons.
German mRNA company Curevac AG has appointed Pierre Kemula as Chief Financial Officer. Kemula joins Curevac from medtech firm Pixium Vision, where he was also responsible for financial activities.
The Royal Swedish Academy of Sciences has awarded the Tobias Prize 2016 to stem cell researcher David Bryder of Lund University for his groundbreaking hematopoietic stem cell discoveries.
Dublin-based protein immunotherapy developer Prothena has appointed Gene Kinney as its new President and Chief Executive Officer. Kinney has also been appointed to Prothena’s Board of Directors.
Swedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma.
Immunotherapy maker TxCell SA has appointed gene therapy expert Olivier Danos to its newly founded Scientific Advisory Board. Danos serves as Senior Vice President of Cell and Gene Therapy at Biogen and has led Biogens gene therapy research group for the last two years. Previously, Danos served as Senior VP Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals.
Six months ago, Andrew Witty, long-time CEO of Britains largest drug maker GlaxoSmithKline, announced he would retire in 2017. Now, GSK has named Emma Walmsley from inside the company as his successor.
German molecular diagnostics specialist GNA Biosolutions GmbH has appointed Frank Krieg-Schneider as its Managing Director and CEO. Krieg-Schneider holds a PhD in molecular genetics from Mainz University and has spent his working life at Qiagen.
Swedish Gyros Protein Technologies AB, which was formed in spring by merging nanoliter-scale immunoassay expert Gyros AB and peptide synthesis instrumentation and reagent provider Protein Technologies Inc., has a new chair. Frank Witney took over as Chairman of the Board of Directors in June.
Galvani Bioelectronics, the developer of bioelectronic medicines launched by GlaxoSmithKline and Alphabets life science play Verily (formerly Google Life Sciences) in early August, will have a bioelectronic visionary on board. Moncef Slaoui, who expedited GSK investments in the field of bioelectronics, will be the chairman of the new companys Board of Directors.